Prospective, randomized, multicenter study of intraosseous basivertebral nerve ablation for the treatment of chronic low back pain: 12-month results.
back pain
chronic pain
outcomes
Journal
Regional anesthesia and pain medicine
ISSN: 1532-8651
Titre abrégé: Reg Anesth Pain Med
Pays: England
ID NLM: 9804508
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
02
11
2020
accepted:
26
04
2021
pubmed:
26
5
2021
medline:
7
8
2021
entrez:
25
5
2021
Statut:
ppublish
Résumé
Vertebral endplates, innervated by the basivertebral nerve (BVN), are a source of chronic low back pain correlated with Modic changes. A randomized trial comparing BVN ablation to standard care (SC) recently reported results of an interim analysis. Here, we report the results of the full randomized trial, including the 3-month and 6-month between-arm comparisons, 12-month treatment arm results, and 6-month outcomes of BVN ablation in the former SC arm. Prospective, open label, 1:1 randomized controlled trial of BVN ablation versus SC in 23 US sites with follow-up at 6 weeks, 3, 6, 9, and 12 months. SC patients were re-baselined and followed up for 6 months post BVN ablation. The primary endpoint was the between-arm comparison of mean Oswestry Disability Index (ODI) change from baseline. Secondary endpoints were Visual Analog Scale (VAS), Short Form (SF-36), EuroQual Group 5 Dimension 5-Level Quality of Life (EQ-5D-5L), responder rates, and rates of continued opioid use. 140 were randomized. Results from BVN ablation (n=66) were superior to SC (n=74) at 3 months for the primary endpoint (mean ODI reduction, difference between arms of -20.3 (CI -25.9 to -14.7 points; p<0.001)), VAS pain improvement (difference of -2.5 cm between arms (CI -3.37 to -1.64, p<0.001)) and quality of life outcomes. At 12 months, basivertebral ablation demonstrated a 25.7±18.5 point reduction in mean ODI (p<0.001), and a 3.8±2.7 cm VAS reduction (p<0.001) from baseline, with 64% demonstrating ≥50% reduction and 29% pain free. Similarly, the former SC patients who elected BVN ablation (92%) demonstrated a 25.9±15.5 point mean ODI reduction (p<0.001) from baseline. The proportion of opioid use did not change in either group (p=0.56). BVN ablation demonstrates significant improvements in pain and function over SC, with treatment results sustained through 12 months in patients with chronic low back pain of vertebrogenic origin.
Identifiants
pubmed: 34031220
pii: rapm-2020-102259
doi: 10.1136/rapm-2020-102259
pmc: PMC8311085
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
683-693Investigateurs
Douglas Beall
(D)
Scott Bainbridge
(S)
Jad Khalil
(J)
Theodore Koreckij
(T)
Paul Kalapos
(P)
Frank Phillips
(F)
John Keel
(J)
Jeffrey Wang
(J)
Matthew Smuck
(M)
Charles Munyon
(C)
John Markman
(J)
Bruce Vrooman
(B)
Neel Anand
(N)
Daniel Lieberman
(D)
Larry Shannon
(L)
Scott Kreiner
(S)
Aaron Calodney
(A)
Ken Yonemura
(K)
Bradly Goodman
(B)
Gregory Moore
(G)
Michael Schaufele
(M)
Dan Nguyen Al Rhyne
(DN)
Informations de copyright
© American Society of Regional Anesthesia & Pain Medicine 2021. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: The following authors declare conflicts of interest related to consulting, teaching/proctoring roles, and/or scientific board roles for Relievant Medsystems: Dr SG, Dr JH, Dr JK and Dr NM. The following authors declare conflicts of interest for research funding paid to their institution from Relievant Medsystem during the conduct of the study: Dr JK, Dr SK, Dr TK, and Dr MS. The following authors declare no conflicts of interest for the submitted work: Dr KB.
Références
Eur Spine J. 2016 Nov;25(11):3723-3734
pubmed: 26914098
Int J Spine Surg. 2019 Apr 30;13(2):110-119
pubmed: 31131209
Neurosurgery. 2017 May 1;80(5):701-715
pubmed: 28327997
BMJ. 1992 Jul 18;305(6846):160-4
pubmed: 1285753
Eur Spine J. 2006 Sep;15(9):1312-9
pubmed: 16896838
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Pain Med. 2018 Nov 1;19(11):2127-2137
pubmed: 29579232
Arch Intern Med. 2009 May 11;169(9):858-66
pubmed: 19433697
Spine J. 2008 Nov-Dec;8(6):968-74
pubmed: 18201937
Spine (Phila Pa 1976). 2009 Sep 1;34(19):2066-76
pubmed: 19701112
Ann Intern Med. 2011 Jul 5;155(1):1-9
pubmed: 21727288
Neurosurgery. 2020 Mar 1;86(3):343-347
pubmed: 31034561
BMJ. 2015 Feb 18;350:h444
pubmed: 25694111
Ann Intern Med. 2003 Jun 3;138(11):871-81
pubmed: 12779297
Cochrane Database Syst Rev. 2010 Jul 07;(7):CD002014
pubmed: 20614428
Global Spine J. 2013 Jun;3(3):153-64
pubmed: 24436866
J Pain. 2006 Mar;7(3):192-9
pubmed: 16516825
Pain. 1983 Sep;17(1):45-56
pubmed: 6226917
Spine (Phila Pa 1976). 2003 Dec 1;28(23):2570-6
pubmed: 14652473
Eur Spine J. 1998;7(5):363-8
pubmed: 9840468
Phys Ther. 2013 Mar;93(3):310-20
pubmed: 23064732
Spine (Phila Pa 1976). 2016 Oct 15;41(20):1606-1612
pubmed: 27035585
Eur Spine J. 2007 Nov;16(11):1776-88
pubmed: 17619914
JAMA. 2017 Feb 14;317(6):642-644
pubmed: 28196244
Eur Spine J. 2018 May;27(5):1146-1156
pubmed: 29423885
Spine (Phila Pa 1976). 2000 Dec 15;25(24):3115-24
pubmed: 11124727
Spine J. 2019 Oct;19(10):1620-1632
pubmed: 31229663
N Engl J Med. 2020 Feb 6;382(6):554-561
pubmed: 32023375
Spine J. 2003 Jan-Feb;3(1):63-7
pubmed: 14589248
J Clin Neurosci. 2021 Feb;84:50-52
pubmed: 33485599
Spine (Phila Pa 1976). 2000 May 15;25(10):1270-7
pubmed: 10806505
JAMA. 2017 Jun 13;317(22):2327-2328
pubmed: 28609520
Eur Spine J. 2020 Aug;29(8):1925-1934
pubmed: 32451777